ZERO Biotech and HKU Filed Patent Applications in Asian Countries

ZERO Biotech announced that the company and The University of Hong Kong (HKU) have filed patent applications on the rights for its proprietary treatment in several additional Asian markets including Singapore, Malaysia, Thailand, Japan, South Korea and Australia. 

The innovative treatment is supported by the positive results of a clinical study conducted in partnership with the Department of Clinical Oncology at HKU. The clinical study was supported by the generous sponsorship of the  'LOVE CAN HELP' Medical Assistance Programme by Li Ka Shing Foundation to provide financial assistance to the individuals and families with medical needs. Dr. Victor Lee, Clinical Associate Professor, Department of Clinical Oncology and the Principal Investigator of the study, said the results of this study are targeted to be published by the end of the year. 

The agreement signing took place in the Technology Transfer Office (TTO), The University of Hong Kong between Clement Tam (CEO, ZERO Biotech) and Ir Dr Alfred Tan (Deputy Director, TTO), and witnessed by Dr. Victor Lee. 

With this expanded patent coverage and compelling clinical data, ZERO Biotech plans to accelerate regulatory submissions and market access activities to make this proprietary treatment available to patients in the expanded territory over the next 12-18 months.